K.J. Harrison & Partners Inc Buys 4,110 Shares of Eli Lilly and Company $LLY

K.J. Harrison & Partners Inc lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 73.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,692 shares of the company’s stock after buying an additional 4,110 shares during the quarter. Eli Lilly and Company comprises 1.1% of K.J. Harrison & Partners Inc’s portfolio, making the stock its 17th largest position. K.J. Harrison & Partners Inc’s holdings in Eli Lilly and Company were worth $7,946,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Bridgewater Advisors Inc. raised its position in shares of Eli Lilly and Company by 0.3% in the 3rd quarter. Bridgewater Advisors Inc. now owns 3,955 shares of the company’s stock worth $3,018,000 after acquiring an additional 11 shares in the last quarter. Key Client Fiduciary Advisors LLC grew its stake in Eli Lilly and Company by 1.2% in the third quarter. Key Client Fiduciary Advisors LLC now owns 1,136 shares of the company’s stock worth $867,000 after purchasing an additional 13 shares during the period. Darwin Wealth Management LLC raised its holdings in Eli Lilly and Company by 3.6% in the third quarter. Darwin Wealth Management LLC now owns 373 shares of the company’s stock worth $285,000 after purchasing an additional 13 shares in the last quarter. Christensen King & Associates Investment Services Inc. lifted its position in Eli Lilly and Company by 1.2% during the third quarter. Christensen King & Associates Investment Services Inc. now owns 1,139 shares of the company’s stock valued at $869,000 after buying an additional 13 shares during the period. Finally, Barnes Dennig Private Wealth Management LLC boosted its holdings in shares of Eli Lilly and Company by 2.1% during the 3rd quarter. Barnes Dennig Private Wealth Management LLC now owns 628 shares of the company’s stock valued at $479,000 after buying an additional 13 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Down 1.1%

NYSE:LLY opened at $1,030.30 on Thursday. The stock has a market cap of $971.95 billion, a price-to-earnings ratio of 44.89, a PEG ratio of 1.21 and a beta of 0.39. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The company’s 50 day moving average price is $1,054.25 and its 200-day moving average price is $924.46. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. During the same period in the prior year, the firm posted $5.32 EPS. The firm’s quarterly revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.7%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 30.15%.

Analyst Upgrades and Downgrades

LLY has been the subject of several research reports. Morgan Stanley increased their price target on shares of Eli Lilly and Company from $1,290.00 to $1,313.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. JPMorgan Chase & Co. raised their target price on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Jefferies Financial Group lifted their target price on shares of Eli Lilly and Company from $976.00 to $1,300.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Cantor Fitzgerald upped their price target on Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $1,300.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1,229.33.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s oral obesity candidate completed an early trial stage, sharpening investor focus on a potential oral GLP‑1/GIP pathway competitor to injectables — a major long‑term revenue lever if translated to late‑stage success. TipRanks: Oral obesity trial completion
• Positive Sentiment: Positive Phase 3 VIVID‑2 open‑label extension results for Omvoh (mirikizumab) bolster Lilly’s non‑GLP‑1 pipeline (Crohn’s/UC), reducing single‑product concentration risk and adding near‑term commercial optionality. Yahoo Finance: VIVID‑2 results
• Positive Sentiment: Analysts have largely stayed constructive: Truist reaffirmed a buy rating and Goldman/Goldman‑coverage notes (and price targets) remain supportive, which can limit downside from headline volatility. MarketScreener: Truist reaffirms buy
• Neutral Sentiment: Bank of America and other firms argue Novo’s announced list‑price cuts are unlikely to meaningfully dent U.S. GLP‑1 volumes for rivals in the near term, suggesting the sector pricing move may be more tactical than market‑eroding. That view helps explain why some investors see the price cut as contained risk rather than an existential threat to Lilly’s sales. Yahoo Finance: BofA sees limited impact
• Neutral Sentiment: Macro/sector coverage pieces and long‑term growth analyses highlight that Lilly’s GLP‑1 blockbusters (Mounjaro/Zepbound) drove a majority of recent revenue growth, keeping the long‑term story intact even as short‑term headlines create choppiness. Zacks: GLP‑1 revenue drivers
• Negative Sentiment: Novo Nordisk announced plans to cut U.S. list prices for Wegovy/Ozempic by up to ~50% starting in 2027 — a direct sector shock that triggered investor worry about pricing pressure, broader margin implications and potential share‑loss dynamics across GLP‑1 makers. That news is the primary reason for today’s downward pressure. Yahoo Finance: Novo halves US price
• Negative Sentiment: Several outlets flagged that investors reacted nervously — and some short‑term selloffs followed — after the Novo pricing announcement and prior trial headlines; that volatility can amplify intraday declines despite Lilly’s strong fundamentals. Fool: Why LLY slumped

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.